BSE filing, NSE: MANGALAM. Summary written from the filing by ALFA Finder's alert engine.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹30.00
- Market cap
- ₹47.48 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 41.3×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Management Change
Mangalam Drugs and Organics appointed Prabhakar Raghunath Zavar as Non-Executive Independent Director for 60 months, effective 15 September 2026. The disclosure covers a board-level appointment with a background profile and no monetary amount.
- Execution
- 60 months
Mangalam Drugs and Organics Board Meeting Date
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr
Mangalam Drugs and Organics Debt & Borrowing: ₹15.57 Cr
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Limited has issued a Postal Ballot notice to seek shareholder approval for appointing Shri Prabhakar Raghunath Zavar as an Independent Director. The appointment is for five years.
Other other announcement announcements
All →M. K. Sons Fine Jewels Other Announcement
M. K. Sons Fine Jewels filed its pre-listing shareholding pattern as of 3 November 2026. It is a routine Regulation 31 disclosure with no transaction.
Ajwa Projects Other Announcement
Ajwa Projects filed its quarterly shareholding pattern as of November 4, 2026. It is a routine Regulation 31 disclosure of pre-listing holdings.
Amwill Health Care Other Announcement
Amwill Health Care committed ₹3 Crore to Nippon India Credit Opportunities AIF Scheme II. The investment, funded from internal accruals, is drawn down in tranches.
- Value
- ₹3.00 Cr
Kenvi Jewels Other Announcement
Kenvi Jewels informs BSE that its RTA, KFIN Technologies, will relocate its corporate office from 1 December 2026, with the registered office unchanged. The RTA appointment terms are unaffected, and shareholders should send correspondence to the new address.
AWL Agri Business Other Announcement
AWL Agri Business filed its quarterly shareholding pattern for the quarter ended 30 September 2026. The filing is routine regulatory disclosure with no transaction.
Sashwat Technocrats Other Announcement
Sashwat Technocrats informed BSE the escrow payment mechanism is not applicable to it. This is a routine compliance clarification with no financial impact.